2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase

Publisher： Bentham Science Publishers

E-ISSN： 1875-6697|12|3|229-240

ISSN： 1573-4099

Source： Current Computer - Aided Drug Design, Vol.12, Iss.3, 2016-09, pp. : 229-240

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

By  

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

By Swaisland H.  

Clinical Pharmacokinetics, Vol. 40, Iss. 4, 2001-01 ,pp. : 297-306

Adis International

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily: Role as Anticancer Agents

By Noonberg S.B.   Benz C.C.  

Drugs, Vol. 59, Iss. 4, 2000-04 ,pp. : 753-767

Adis International

Access to resources Recommend Favorite

A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

By Iyer Renuka   Bharthuar Anubha  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 311-320

Informa Healthcare

Access to resources Recommend Favorite

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials

By Ciardiello Fortunato   De Vita Ferdinando   Orditura Michele   De Placido Sabino   Tortora Giampaolo  

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. : 501-514

Informa Healthcare

Access to resources Recommend Favorite